PipelineReview.com3h
Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025
BAGSVAERD, Denmark I March 29, 2025 I Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® ...
The Lancet20h
Increasing walking capacity in patients with peripheral artery disease
The treatment of many patients with peripheral artery disease is not optimal, and indeed is much worse than that in patients ...
Taiwan News17h
Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025
Based on data from the SOUL clinical trial, Novo Nordisk submitted a label extension application for Rybelsus ®, which has been accepted for review by the European Medicines Agency (EMA) and the US ...
Healio21h
Ozempic boosts walking distance for patients with diabetes, peripheral artery disease
Among patients with diabetes and peripheral artery disease, semaglutide 1 mg increased walking distance vs. placebo, ...